Crohn's Disease Pipeline Shows Strong Momentum as 90+ Pharma Companies Advance Novel Inflammatory Bowel Disease Therapies, Finds DelveInsight | AbbVie, Janssen, Merck, Takeda, Roche

There are 90+ key companies, including AbbVie, Janssen, Merck, Takeda, Roche, AgomAb Therapeutics, Pfizer, Amgen, and others, developing therapies for Crohn's disease, with companies like Janssen and Roche having candidates in the most advanced Phase III stage.
DelveInsight's "Crohn's Disease - Pipeline Insight, 2026" report provides comprehensive insights about 90+ companies developing over 90 pipeline drugs in the Crohn's Disease pipeline landscape. It covers the Crohn's Disease pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Crohn's Disease treatment landscape. Learn more about the evolving Crohn's Disease pipeline today @ https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Crohn's Disease Pipeline Report

*
On April 15, 2026, AbbVie initiated a Phase 3 study to evaluate the safety and efficacy of oral Upadacitinib in treating moderately to severely active Crohn's disease in pediatric participants aged 2 to 18 years.

*
On April 13, 2026, Janssen-Cilag Ltd. conducted a Phase 3b study to evaluate the efficacy of guselkumab in achieving transmural healing based on Magnetic Resonance Index of Activity (MaRIA) scans at Week 48.

*
On April 13, 2026, Merck Sharp & Dohme LLC initiated a Phase 3 study to test if at least one tulisokibart dose level is superior to placebo in achieving clinical remission.

*
On April 13, 2026, Takeda conducted a Phase 2b study to determine if three different doses of TAK-279 reduce bowel inflammation and ulcers compared to placebo after 12 weeks of treatment.

*
On April 13, 2026, Janssen Research & Development LLC announced a Phase 3 study evaluating the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's disease at Week 52.

*
On April 06, 2026, Sanofi conducted a Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's disease.

*
Crohn's disease is a chronic relapsing inflammatory condition of the gastrointestinal tract that affects millions worldwide, often requiring lifelong management through medication or surgery.

*
DelveInsight's Crohn's Disease Pipeline Insight report identifies a robust clinical landscape with 90+ active players advancing more than 90 pipeline therapies across various stages of development.

*
Promising Crohn's disease therapies in development include Guselkumab, RO7790121, AGMB-129, and other clinical-stage candidates spanning monoclonal antibodies, small molecules, and gene therapies.

Download for updates and the latest revolution in Crohn's disease care @ Crohn's Disease Market Insight, Epidemiology And Market Forecast [https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Crohn's Disease Emerging Drugs Profile

Guselkumab: Janssen Pharmaceutical

Guselkumab is a fully-human immunoglobulin G1 lambda (IgG1) monoclonal antibody that selectively blocks interleukin-23 (IL-23). By inhibiting IL-23, guselkumab aims to reduce inflammation in patients with moderately to severely active Crohn's disease. Currently, guselkumab is undergoing Phase III clinical evaluation to assess its safety and efficacy in achieving clinical and endoscopic remission.

RO7790121: Roche

RO7790121 is an investigational monoclonal antibody developed by Roche to inhibit tumor necrosis factor-like ligand 1A (TL1A). By targeting TL1A, the drug aims to reduce abnormal immune responses and control inflammation in the gut. Currently, RO7790121 is being evaluated in Phase III clinical trials for the treatment of moderately to severely active Crohn's disease.

AGMB-129: AgomAb Therapeutics

AGMB-129 is an oral, small molecule GI-restricted inhibitor of ALK5 (or TGF- RI) specifically developed for fibrostenosing Crohn's disease (FSCD). TGF- is recognized as a major driver of fibrosis, and AGMB-129 is designed to deliver high local exposure in the ileum with minimal systemic exposure to improve safety. Currently, AGMB-129 is in Phase II clinical trial evaluation and has received FDA Fast Track Designation.

For more information on the Crohn's Disease Emerging Drugs Profile, download DelveInsight's comprehensive Crohn's Disease Pipeline Insight report [https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The Crohn's Disease Pipeline Report Provides

*
Detailed insights about companies developing therapies for Crohn's disease, with aggregate therapies developed by each company.

*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Crohn's disease treatment.

*
Crohn's disease companies involved in targeted therapeutics development with respective active and inactive projects.

*
Crohn's disease drugs under development based on stage, route of administration, target receptor, monotherapy or combination therapy, and molecule type.

*
Detailed analysis of collaborations, licensing agreements, and financing details for future advancement of the Crohn's disease market.

Learn more about Crohn's disease drug opportunities in our comprehensive Crohn's disease pipeline report @ Crohn's Disease Unmet Needs [https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Crohn's Disease Companies and Competitive Landscape

There are 90+ key companies, including AbbVie, Janssen, Merck, Takeda, Roche, AgomAb Therapeutics, Pfizer, Amgen, and others, developing therapies for Crohn's disease, with companies like Janssen and Roche having candidates in the most advanced Phase III stage.

DelveInsight's Crohn's disease pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

*
Oral

*
Intravenous

*
Subcutaneous

*
Intramuscular

*
Topical

*
Molecule Type

Crohn's disease products have been categorized under various Molecule types such as:

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

Discover the latest advancements in Crohn's disease treatment by visiting our website. Stay informed @ Crohn's Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/crohns-disease-cd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Scope of the Crohn's Disease Pipeline Report

*
Coverage: Global

*
Crohn's Disease Companies: AbbVie, Janssen, Merck, Takeda, Roche, AgomAb Therapeutics, Pfizer, Amgen, and others.

*
Crohn's Disease Therapies: Guselkumab, RO7790121, AGMB-129, TAK-279, Tulisokibart, and other pipeline candidates.

*
Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

*
Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

*
Introduction

*
Executive Summary

*
Crohn's Disease: Overview

*
Pipeline Therapeutics

*
Therapeutic Assessment

*
Crohn's Disease - DelveInsight's Analytical Perspective

*
Late Stage Products (Phase III)

*
Mid Stage Products (Phase II)

*
Early Stage Products (Phase I)

*
Preclinical and Discovery Stage Products

*
Inactive Products

*
Crohn's Disease Key Companies

*
Crohn's Disease Key Products

*
Crohn's Disease Unmet Needs

*
Crohn's Disease Market Drivers and Barriers

*
Crohn's Disease Future Perspectives and Conclusion

*
Crohn's Disease Analyst Views

*
Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=crohns-disease-pipeline-shows-strong-momentum-as-90-pharma-companies-advance-novel-inflammatory-bowel-disease-therapies-finds-delveinsight-abbvie-janssen-merck-takeda-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.